CV Sciences (CVSI) Net Income towards Common Stockholders Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Net Income towards Common Stockholders Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 15.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.58% |
| Mar 31, 2026 | -28.32% |
| Dec 31, 2025 | 27.44% |
| Sep 30, 2025 | 28.18% |
| Jun 30, 2025 | 58.20% |
| Mar 31, 2025 | 62.79% |
| Dec 31, 2024 | 62.56% |
| Sep 30, 2024 | -125.06% |
| Jun 30, 2024 | 45.10% |
| Mar 31, 2024 | 41.44% |
| Dec 31, 2023 | 54.61% |
| Sep 30, 2023 | 47.88% |
| Jun 30, 2023 | 34.96% |
| Mar 31, 2023 | 45.93% |
| Dec 31, 2022 | 29.80% |
| Sep 30, 2022 | 16.47% |
| Jun 30, 2022 | -69.93% |
| Mar 31, 2022 | 39.14% |
| Dec 31, 2021 | -71.60% |
| Sep 30, 2021 | -26.25% |